PRESS RELEASE

Q1 2021 — Press release

Q1 2021PDF · 18 pages292 KB
JOHNSON & JOHNSON REPORTS 2021 FIRST-QUARTER RESULTS:
• 	2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of
5.5%* and adjusted operational growth of 6.0%*
• 	2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%*
• 	Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%*
and adjusted operational EPS growth to 16.8%* at the midpoint
New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter.
“Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our
Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky, Chairman and Chief
Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-
enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our
business and the dedication of the 135,000 employees of Johnson & Johnson who strive every day to profoundly
change the trajectory of health for humanity and make healthier communities for everyone, everywhere.”
OVERALL FINANCIAL RESULTS:
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
REGIONAL SALES RESULTS:

-- 1 of 18 --

2
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
SEGMENT SALES RESULTS:
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
First-Quarter 2021 SEGMENT COMMENTARY:
Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%*
primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-
the counter products. Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON’S BABY
in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter
products.
Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%*
driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for
the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation
androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for
the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,
INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical
antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved
for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was partially offset

-- 2 of 18 --

3
by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the
treatment of a number of immune-mediated inflammatory diseases, and U.S. ZYTIGA (abiraterone acetate), an oral,
once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant
prostate cancer.
Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*,
and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were
electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and
international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery
in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.

-- 3 of 18 --

4
NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures
filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on
Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases
available online in the Investors section of the company’s website at news releases.
Regulatory
Decisions
PONVORY (ponesimod) approved by U.S. FDA, an oral treatment for adults with relapsing
multiple sclerosis proven superior to (teriflunomide) in reducing annual relapses and brain
lesions
(press release)
Johnson & Johnson Single-Shot COVID-19 Vaccine granted conditional marketing
authorization by European Commission
(press release)
Johnson & Johnson Single-Shot COVID-19 Vaccine granted emergency use listing by the
World Health Organization
(press release)
Johnson & Johnson COVID-19 Vaccine authorized by U.S. FDA for emergency use 	(press release)
SPRAVATO (Esketamine Nasal Spray) authorized in Europe for the rapid reduction of
depressive symptoms in a psychiatric emergency for patients with major depressive disorder (press release)
MONOFOCAL INTRAOCULAR LENS - TECNIS EYHANCE AND TECNIS EYHANCE
TORIC II IOLS - receives FDA approval for a next generation treatment for cataract patients
(press release)
Regulatory
Submission
Submission of supplemental new drug application to U.S. FDA by ViiV Healthcare for
expanded use of CABENUVA (rilpivirine and cabotegravir) as an HIV treatment for use
every two months
(press release)
Other
Janssen provides update on Phase 3 ACIS Study in patients with metastatic castration-
resistant prostate cancer treated with ERLEADA (apalutamide) and ZYTIGA (abiraterone
acetate) plus prednisone combination ¹
(press release)
Johnson & Johnson announces advance purchase agreement with the African Vaccine
Acquisition Trust for the Company’s COVID-19 vaccine candidate (press release)
PONVORY (ponesimod) receives positive CHMP opinion for the treatment of adults with
relapsing forms of multiple sclerosis with active disease defined by clinical or imaging
features
(press release)
CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) accepted for accelerated assessment
in Europe for the treatment of patients with heavily pretreated multiple myeloma
(press release)
1 Subsequent to the quarter

-- 4 of 18 --

5
FULL-YEAR 2021 GUIDANC E:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is
unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses,
acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items
are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in
accordance with GAAP.
($ in Billions, except EPS) 	January 2021 	April 2021
Adjusted Operational Sales1,2
Change vs. Prior Year 8.0% - 9.5% 	8.7% - 9.9%
Operational Sales2
Change vs. Prior Year
$88.8B - $90.0B
7.5% – 9.0%
$89.3B - $90.3B
8.2% – 9.4%
Estimated Reported Sales3
Change vs. Prior Year
$90.5B - $91.7B
9.5% – 11.0%
$90.6B - $91.6B
9.7% – 10.9%
Adjusted Operational EPS (Diluted)2,4
Change vs. Prior Year
$9.25 - $9.45
15.2% - 17.7%
$9.30 - $9.45
15.8% - 17.7%
Adjusted EPS (Diluted)3,4
Change vs. Prior Year
$9.40 - $9.60
17.1% - 19.6%
$9.42 - $9.57
17.3% - 19.2%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: January 2021 = $1.21 and April 2021 = $1.19 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
Other modeling considerations will be provided on the webcast.
WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m.,
Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting
the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast
in the Investors section of the company's website at events-and-presentations.
ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward
progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life.
Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and
size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind,
body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to
profoundly change the trajectory of health for humanity.

-- 5 of 18 --

6
NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding
the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted
diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible
amortization expense and special items, are non-GAAP financial measures and should not be considered
replacements for, and should be read together with, the most comparable GAAP financial measures. Except for
guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP
financial measures can be found in the accompanying financial schedules of the earnings release and the Investors
section of the company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at
quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of
earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information
on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected
compounds in late stage development and a copy of today’s earnings call presentation can also be found in the
Investors section of the company's website at quarterly-results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of
1995 regarding, among other things: future operating and financial performance, product development, market position
and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are
based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks
or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson &
Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global
pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented
in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to
the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic,
economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological
advances, new products and patents attained by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial
success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the
Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls
or regulatory action; significant adverse litigation or government action, including related to product liability claims;
changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health
care cost containment; changes in behavior and spending patterns of purchasers of health care products and services;
financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health
care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can
be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 including in
the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the
Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the
Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on
request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of
this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new
information or future events or developments.
Press Contacts: 	Investor Contacts:
Christina Chan 	Courtney Dugan 	Christopher DelOrefice 	Sarah Wood
(732) 524-6297 	(347) 452-1061 	(732) 524-2955 	(732) 524-2617

-- 6 of 18 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2021 	2020 	Total 	Operations 	Currency
Sales to customers by
segment of business
Consumer Health
U.S. 	1,611	$ 	1,740 	(7.4) % 	(7.4) 	-
International 	1,932 	1,885 	2.5 	0.5 	2.0
3,543 	3,625 	(2.3) 	(3.3) 	1.0
Pharmaceutical
U.S. 	6,446 	6,061 	6.4 	6.4 	-
International 	5,753 	5,073 	13.4 	7.9 	5.5
12,199 	11,134 	9.6 	7.1 	2.5
Medical Devices
U.S. 	3,054 	2,898 	5.4 	5.4 	-
International 	3,525 	3,034 	16.2 	10.5 	5.7
6,579 	5,932 	10.9 	8.0 	2.9
U.S. 	11,111 	10,699 	3.9 	3.9 	-
International 	11,210 	9,992 	12.2 	7.3 	4.9
Worldwide 	22,321	$ 	20,691 	7.9 % 	5.5 	2.4
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FIRST QUARTER
Percent Change

-- 7 of 18 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2021 	2020 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	11,111	$ 	10,699 	3.9 	% 	3.9 	-
Europe 	5,414 	4,827 	12.1 	4.7 	7.4
Western Hemisphere excluding U.S. 	1,424 	1,502 	(5.1) 	0.0 	(5.1)
Asia-Pacific, Africa 	4,372 	3,663 	19.4 	13.7 	5.7
International 	11,210 	9,992 	12.2 	7.3 	4.9
Worldwide 	22,321	$ 	20,691 	7.9 	% 	5.5 	2.4
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FIRST QUARTER
Percent Change

-- 8 of 18 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	22,321	$ 	100.0 	20,691	$ 	100.0 	7.9
Cost of products sold 	7,063 	31.7 	7,062 	34.1 	0.0
Gross Profit 	15,258 	68.3 	13,629 	65.9 	12.0
Selling, marketing and administrative expenses 	5,432 	24.3 	5,203 	25.1 	4.4
Research and development expense 	3,178 	14.2 	2,580 	12.5 	23.2
Interest (income) expense, net 	48 	0.2 	(42) 	(0.2)
Other (income) expense, net 	(882) 	(3.9) 	(679) 	(3.3)
Restructuring 	53 	0.2 	58 	0.3
Earnings before provision for taxes on income 	7,429 	33.3 	6,509 	31.5 	14.1
Provision for taxes on income 	1,232 	5.5 	713 	3.5 	72.8
Net earnings 	6,197 	27.8 	5,796 	28.0 	6.9
Net earnings per share (Diluted) 	2.32	$ 	2.17	$ 	6.9
Average shares outstanding (Diluted) 	2,672.7 	2,671.0
Effective tax rate 	16.6 % 	11.0 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	8,291	$ 	37.1 	7,244	$ 	35.0 	14.5
Net earnings 	6,924	$ 	31.0 	6,154	$ 	29.7 	12.5
Net earnings per share (Diluted) 	2.59	$ 	2.30	$ 	12.6
Effective tax rate 	16.5 % 	15.0 %
(1) See Reconciliation of Non-GAAP Financial Measures.
FIRST QUARTER
2021 	2020

-- 9 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2021 	2020
Net Earnings, after tax- as reported 	$6,197 	$5,796
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,215 	1,118
Litigation expense 	- 	120
Restructuring related 	104 	118
Acquisition, integration and divestiture related 1 	(538) 	(962)
Unrealized (gains)/losses on securities 	35 	327
Medical Device Regulation 	46 	14
Tax Adjustments
Tax impact on special item adjustments 2 	(113) 	(267)
Tax legislation and other tax related 	(22) 	(110)
Adjusted Net Earnings, after tax 	$6,924 	$6,154
Average shares outstanding (Diluted) 	2,672.7 	2,671.0
Adjusted net earnings per share (Diluted) 	$2.59 	$2.30
Operational adjusted net earnings per share (Diluted) 	$2.49
Notes:
1
2
First Quarter
Acquisition, integration and divestiture related for the first quarter of 2021 primarily includes the gain on the divestiture of 2
Pharmaeutical brands outside of the U.S. The first quarter of 2020 primarily includes a $983M Contingent Consideration reversal
related to the timing of certain developmental milestones associated with the Auris Health acquisition.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax
special items in arriving at adjusted earnings.

-- 10 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	(2.3)% 	9.6% 	10.9% 	7.9%
U.S. 	(7.4)% 	6.4% 	5.4% 	3.9%
International 	2.5% 	13.4% 	16.2% 	12.2%
WW Currency 	1.0 	2.5 	2.9 	2.4
U.S. 	- 	- 	- 	-
International 	2.0 	5.5 	5.7 	4.9
WW Operational 	(3.3)% 	7.1% 	8.0% 	5.5%
U.S. 	(7.4)% 	6.4% 	5.4% 	3.9%
International 	0.5% 	7.9% 	10.5% 	7.3%
General Surgery
Advanced Sterilization Products 	0.6 	0.2
U.S. 	0.0 	0.0
International 	1.2 	0.4
All Other Acquisitions and Divestitures 	0.4 	0.3 	0.1 	0.3
U.S. 	0.5 	(0.2) 	0.2 	0.0
International 	0.4 	0.9 	0.0 	0.5
WW Adjusted Operational 	(2.9)% 	7.4% 	8.8% 	6.0%
U.S. 	(6.9)% 	6.2% 	5.6% 	3.9%
International 	0.9% 	8.8% 	11.8% 	8.2%
Adjusted Operational Sales Growth
FIRST QUARTER 2021 ACTUAL vs. 2020 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 11 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2021 	2020 	Reported 	Operational (1) 	Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US 	599	$ 	689 	-13.0% 	-13.0% 	-
Intl 	575 	659 	-12.8% 	-16.6% 	3.8%
WW 	1,175 	1,348 	-12.9% 	-14.8% 	1.9%
SKIN HEALTH / BEAUTY
US 	634 	659 	-3.9% 	-3.9% 	-
Intl 	529 	458 	15.7% 	12.3% 	3.4%
WW 	1,163 	1,117 	4.1% 	2.8% 	1.3%
ORAL CARE
US 	163 	176 	-7.2% 	-7.2% 	-
Intl 	254 	219 	16.0% 	13.9% 	2.1%
WW 	417 	395 	5.7% 	4.5% 	1.2%
BABY CARE
US 	96 	92 	4.2% 	4.2% 	-
Intl 	293 	269 	8.9% 	11.3% 	-2.4%
WW 	389 	361 	7.7% 	9.5% 	-1.8%
WOMEN'S HEALTH
US 	3 	4 	-25.8% 	-25.8% 	-
Intl 	219 	228 	-3.9% 	-2.2% 	-1.7%
WW 	222 	232 	-4.3% 	-2.6% 	-1.7%
WOUND CARE / OTHER
US 	115 	119 	-3.0% 	-3.0% 	-
Intl 	61 	52 	17.6% 	14.2% 	3.4%
WW 	177 	171 	3.3% 	2.2% 	1.1%
TOTAL CONSUMER HEALTH
US 	1,611 	1,740 	-7.4% 	-7.4% 	-
Intl 	1,932 	1,885 	2.5% 	0.5% 	2.0%
WW 	3,543	$ 	3,625 	-2.3% 	-3.3% 	1.0%
See footnotes at end of schedule
% Change

-- 12 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
PHARMACEUTICAL SEGMENT (2,3) 	2021 	2020 	Reported 	Operational (1) 	Currency
IMMUNOLOGY
US 	2,413	$ 	2,410 	0.1% 	0.1% 	-
Intl 	1,501 	1,228 	22.3% 	15.9% 	6.4%
WW 	3,914 	3,638 	7.6% 	5.5% 	2.1%
REMICADE
US 	489 	625 	-21.7% 	-21.7% 	-
US Exports (4) 	57 	110 	-48.4% 	-48.4% 	-
Intl 	232 	256 	-9.4% 	-12.1% 	2.7%
WW 	777 	990 	-21.5% 	-22.2% 	0.7%
SIMPONI / SIMPONI ARIA
US 	255 	272 	-5.9% 	-5.9% 	-
Intl 	307 	258 	18.9% 	13.8% 	5.1%
WW 	562 	529 	6.2% 	3.7% 	2.5%
STELARA
US 	1,331 	1,217 	9.4% 	9.4% 	-
Intl 	817 	603 	35.6% 	27.6% 	8.0%
WW 	2,148 	1,819 	18.1% 	15.4% 	2.7%
TREMFYA
US 	274 	187 	46.3% 	46.3% 	-
Intl 	143 	109 	32.0% 	23.1% 	8.9%
WW 	418 	296 	41.0% 	37.8% 	3.2%
OTHER IMMUNOLOGY
US 	7 	- 	* 	* 	-
Intl 	2 	3 	-38.4% 	-36.3% 	-2.1%
WW 	8 	3 	* 	* 	*
INFECTIOUS DISEASES
US 	512 	436 	17.4% 	17.4% 	-
Intl 	494 	483 	2.3% 	-2.2% 	4.5%
WW 	1,007 	920 	9.5% 	7.1% 	2.4%
COVID-19 VACCINE
US 	100 	- 	* 	* 	-
Intl 	- 	- 	- 	- 	-
WW 	100 	- 	* 	* 	-
EDURANT / rilpivirine
US 	10 	12 	-12.3% 	-12.3% 	-
Intl 	233 	212 	9.8% 	0.9% 	8.9%
WW 	243 	224 	8.6% 	0.2% 	8.4%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	380 	396 	-3.8% 	-3.8% 	-
Intl 	166 	184 	-9.9% 	-10.4% 	0.5%
WW 	546 	579 	-5.8% 	-5.9% 	0.1%
OTHER INFECTIOUS DISEASES
US 	21 	29 	-27.0% 	-27.0% 	-
Intl 	96 	87 	9.7% 	7.4% 	2.3%
WW 	117 	116 	0.6% 	-1.2% 	1.8%
% Change

-- 13 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2021 	2020 	Reported 	Operational (1) 	Currency
NEUROSCIENCE
US 	771 	748 	3.2% 	3.2% 	-
Intl 	949 	910 	4.3% 	0.4% 	3.9%
WW 	1,721 	1,658 	3.8% 	1.6% 	2.2%
CONCERTA / Methylphenidate
US 	47 	52 	-9.6% 	-9.6% 	-
Intl 	123 	118 	4.5% 	-0.4% 	4.9%
WW 	171 	171 	0.2% 	-3.2% 	3.4%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	589 	544 	8.3% 	8.3% 	-
Intl 	376 	339 	11.0% 	4.5% 	6.5%
WW 	965 	883 	9.4% 	6.9% 	2.5%
RISPERDAL CONSTA
US 	67 	76 	-11.8% 	-11.8% 	-
Intl 	89 	94 	-4.8% 	-8.8% 	4.0%
WW 	157 	170 	-7.9% 	-10.1% 	2.2%
OTHER NEUROSCIENCE
US 	67 	75 	-9.8% 	-9.8% 	-
Intl 	361 	360 	0.2% 	-0.9% 	1.1%
WW 	428 	435 	-1.5% 	-2.5% 	1.0%
ONCOLOGY
US 	1,377 	1,175 	17.2% 	17.2% 	-
Intl 	2,193 	1,839 	19.3% 	12.9% 	6.4%
WW 	3,570 	3,013 	18.5% 	14.6% 	3.9%
DARZALEX
US 	691 	463 	49.2% 	49.2% 	-
Intl 	674 	474 	42.2% 	35.3% 	6.9%
WW 	1,365 	937 	45.6% 	42.2% 	3.4%
ERLEADA
US 	171 	119 	44.0% 	44.0% 	-
Intl 	90 	24 	* 	* 	*
WW 	261 	143 	82.8% 	79.7% 	3.1%
IMBRUVICA
US 	444 	432 	2.8% 	2.8% 	-
Intl 	680 	599 	13.5% 	7.6% 	5.9%
WW 	1,125 	1,031 	9.0% 	5.6% 	3.4%
ZYTIGA / abiraterone acetate
US 	50 	139 	-64.2% 	-64.2% 	-
Intl 	588 	552 	6.6% 	0.0% 	6.6%
WW 	638 	690 	-7.6% 	-12.9% 	5.3%
OTHER ONCOLOGY (5)
US 	21 	22 	-5.1% 	-5.1% 	-
Intl 	161 	190 	-15.3% 	-19.3% 	4.0%
WW 	182 	212 	-14.2% 	-17.9% 	3.7%
% Change

-- 14 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2021 	2020 	Reported 	Operational (1) 	Currency
PULMONARY HYPERTENSION
US 	573 	486 	18.0% 	18.0% 	-
Intl 	288 	260 	10.8% 	5.6% 	5.2%
WW 	861 	745 	15.5% 	13.7% 	1.8%
OPSUMIT
US 	272 	229 	18.5% 	18.5% 	-
Intl 	179 	160 	11.5% 	6.3% 	5.2%
WW 	450 	389 	15.6% 	13.5% 	2.1%
UPTRAVI
US 	259 	212 	21.9% 	21.9% 	-
Intl 	46 	38 	23.0% 	15.7% 	7.3%
WW 	305 	250 	22.0% 	20.9% 	1.1%
OTHER PULMONARY HYPERTENSION
US 	42 	44 	-3.5% 	-3.5% 	-
Intl 	63 	62 	1.4% 	-2.1% 	3.5%
WW 	105 	106 	-0.6% 	-2.7% 	2.1%
CARDIOVASCULAR / METABOLISM / OTHER
US 	799 	806 	-0.9% 	-0.9% 	-
Intl 	328 	354 	-7.2% 	-11.3% 	4.1%
WW 	1,127 	1,160 	-2.8% 	-4.1% 	1.3%
XARELTO
US 	589 	527 	11.7% 	11.7% 	-
Intl 	- 	- 	- 	- 	-
WW 	589 	527 	11.7% 	11.7% 	-
INVOKANA / INVOKAMET
US 	87 	117 	-26.1% 	-26.1% 	-
Intl 	63 	58 	9.2% 	4.2% 	5.0%
WW 	150 	175 	-14.4% 	-16.1% 	1.7%
PROCRIT / EPREX
US 	62 	76 	-18.3% 	-18.3% 	-
Intl 	64 	79 	-18.1% 	-22.2% 	4.1%
WW 	127 	155 	-18.2% 	-20.3% 	2.1%
OTHER
US 	60 	85 	-28.8% 	-28.8% 	-
Intl 	201 	217 	-7.7% 	-11.5% 	3.8%
WW 	261 	302 	-13.6% 	-16.4% 	2.8%
TOTAL PHARMACEUTICAL
US 	6,446 	6,061 	6.4% 	6.4% 	-
Intl 	5,753 	5,073 	13.4% 	7.9% 	5.5%
WW 	12,199	$ 	11,134 	9.6% 	7.1% 	2.5%
See footnotes at end of schedule
% Change

-- 15 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
MEDICAL DEVICES SEGMENT (2) 	2021 	2020 	Reported 	Operational (1) 	Currency
INTERVENTIONAL SOLUTIONS
US 	434	$ 	365 	19.0% 	19.0% 	-
Intl 	514 	362 	42.0% 	34.0% 	8.0%
WW 	949 	727 	30.4% 	26.4% 	4.0%
ORTHOPAEDICS
US 	1,249 	1,250 	-0.1% 	-0.1% 	-
Intl 	864 	788 	9.7% 	3.1% 	6.6%
WW 	2,113 	2,038 	3.7% 	1.2% 	2.5%
HIPS
US 	210 	206 	2.4% 	2.4% 	-
Intl 	146 	132 	11.2% 	4.5% 	6.7%
WW 	357 	337 	5.8% 	3.2% 	2.6%
KNEES
US 	185 	214 	-13.5% 	-13.5% 	-
Intl 	132 	130 	2.0% 	-4.1% 	6.1%
WW 	317 	343 	-7.6% 	-9.9% 	2.3%
TRAUMA
US 	450 	407 	10.7% 	10.7% 	-
Intl 	282 	247 	14.4% 	7.7% 	6.7%
WW 	733 	654 	12.1% 	9.5% 	2.6%
SPINE, SPORTS & OTHER
US 	403 	423 	-4.8% 	-4.8% 	-
Intl 	303 	280 	8.4% 	1.7% 	6.7%
WW 	706 	703 	0.4% 	-2.2% 	2.6%
% Change

-- 16 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2021 	2020 	Reported 	Operational (1) 	Currency
SURGERY
US 	898 	844 	6.5% 	6.5% 	-
Intl 	1,474 	1,257 	17.3% 	11.7% 	5.6%
WW 	2,372 	2,100 	12.9% 	9.6% 	3.3%
ADVANCED
US 	405 	381 	6.5% 	6.5% 	-
Intl 	713 	567 	25.7% 	19.5% 	6.2%
WW 	1,118 	948 	18.0% 	14.3% 	3.7%
GENERAL
US 	493 	463 	6.5% 	6.5% 	-
Intl 	761 	690 	10.3% 	5.3% 	5.0%
WW 	1,254 	1,153 	8.8% 	5.8% 	3.0%
VISION
US 	472 	439 	7.4% 	7.4% 	-
Intl 	673 	628 	7.3% 	3.9% 	3.4%
WW 	1,145 	1,067 	7.3% 	5.4% 	1.9%
CONTACT LENSES / OTHER
US 	371 	346 	7.2% 	7.2% 	-
Intl 	486 	467 	4.0% 	0.9% 	3.1%
WW 	857 	814 	5.3% 	3.5% 	1.8%
SURGICAL
US 	101 	93 	8.2% 	8.2% 	-
Intl 	187 	160 	17.0% 	12.9% 	4.1%
WW 	288 	253 	13.7% 	11.2% 	2.5%
TOTAL MEDICAL DEVICES
US 	3,054 	2,898 	5.4% 	5.4% 	-
Intl 	3,525 	3,034 	16.2% 	10.5% 	5.7%
WW 	6,579	$ 	5,932 	10.9% 	8.0% 	2.9%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
(5) Refer to supplemental schedule
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
% Change

-- 17 of 18 --

Full Year 	Q1 	Q2 	Q3 	Q4 	Full Year
PHARMACEUTICAL SEGMENT(1)
Oncology
OTHER ONCOLOGY(2)
US 	70 	22 	20 	21 	20 	83
Intl 	1,087 	190 	185 	181 	183 	738
WW 	1,158 	212 	204 	203 	202 	821
Note: Columns and rows within tables may not add due to rounding.
(1) Unaudited
(2) Other Oncology is inclusive of VELCADE, which was previously disclosed separately
Supplemental Sales Information
(Dollars in Millions)
Prior quarter amounts have been reclassified to
conform to current quarter product disclosure
2019 	2020 	2020

-- 18 of 18 --